Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Study: GlaxoSmithKline's Mekinist, Tafinlar combination shows survival benefit versus Roche's Zelboraf in melanoma
Study: GlaxoSmithKline's Mekinist, Tafinlar combination shows survival benefit versus Roche's Zelboraf in melanoma
Study: GlaxoSmithKline's Mekinist, Tafinlar combination shows survival benefit versus Roche's Zelboraf in melanoma
Submitted by
admin
on July 17, 2014 - 10:12am
Source:
First Word Pharma
News Tags:
GSK
Mekinist
Tafinlar
Zelboraf
melanoma
Headline:
Study: GlaxoSmithKline's Mekinist, Tafinlar combination shows survival benefit versus Roche's Zelboraf in melanoma
Do Not Allow Advertisers to Use My Personal information
